Vaccines independent medical education

GSK Vaccines: Support for Independent Medical Education

Independent Medical Education (IME) projects eligible for GSK Vaccines’ support via this application process include educational activities in general vaccinology or specific disease areas in which GSK Vaccines has marketed products.

For funding requests targeting a single country, local GSK offices should be contacted.

For US-based organizations requesting grant funding to support IME activities for US-based healthcare professionals, different guidelines apply and this process is not applicable. Please visit for details.

The target recipients of the IME supported by this program should come from a broad international audience.

Recipient programs will develop the knowledge and practice of healthcare professionals in order that they can make the most appropriate curative or preventive treatment decisions for their patients.

GSK-funded IME activities are supported through funding at arm's-length by GSK. This means free from GSK influence on content development and faculty, participant and logistic selection. IME programs developed in this independent way provide a balanced perspective on the subject matter, putting the patient first.  Organizations will be assessed according to defined criteria (below).

Travel Grants: Funding to support the travel and accommodation of attendees to reputable and renowned scientific meetings should be requested through the GSK Vaccines “Support for Travel Sponsorship for global/international IME activities or scientific congresses” request process.

Areas of interest for Independent Medical Education

GSK Vaccines has identified areas of interest where we and others have seen gaps in medical education related to disease areas where GSK has marketed products, as well as in general areas of vaccinology.

These are shared to enable organizations that have the skills, capability and credentials to deliver high-quality medical education to submit requests for funding from GSK to support such programmes.

Criteria for Independent Medical Education

GSK Vaccines will evaluate requests for funding based on essential criteria which include:

  • Assessment of the type of organization requesting funding (Academic institution that trains healthcare professionals/ medical education charity that educates healthcare professionals/ patient group/ professional medical or scientific association or society/ healthcare service provider that employs healthcare professionals)
  • Evidence of complete independence from any promotional activities related to GSK
  • Absence of Conflicts of Interest in delivering medical education and in receiving funding from GSK
  • Ability to measure Medical Education Desired Results (see Moore DE, et al. J Contin Educ Health Prof. 2009;29:1-15.  Achieving Desired Results and Improved Outcomes: Integrating Planning and Assessment Throughout Learning Activities)
  • Agreement from the recipient programme to be subject to potential independent audit to review quality of education delivered and use of funds provided.

Other local requirements and legislation related to medical education will also be considered.

Contact for Independent Medical Education

Should your organization wish to seek funding in any of the areas of interest, please contact us using our dedicated mailbox for requests ( managed within Worldwide Vaccinology, Vaccine Education and Medical Training. Details of the process for submissions will be provided following initial contact. 

Timelines for Independent Medical Education Grant Requests

Please note that Grants requests are reviewed on a monthly basis at GSK hence submissions should be made at least 6 months prior to the event for which funding is sought.

Areas of Interest for Independent Medical Education

Herpes zoster

  • The clinical burden and public health impact of herpes Zoster disease, the importance of prevention and vaccination as a key tool.
  • Vaccination strategies to support healthy ageing and for overcoming the age-related decline in immunity.
  • Clinical Profiles of the available Vaccines for Herpes Zoster prevention
  • The need for and safety of modern vaccine technologies, including adjuvant systems

Pediatric pneumococcal diseases prevention

  • The burden of pediatric pneumococcal disease
  • Efficacy, impact and safety of pneumococcal conjugate vaccines (PCV)
  • Experience with implementation of pneumococcal conjugate vaccines
  • Cost effectiveness of pneumococcal vaccines

Meningococcal meningitis prevention

  • Persistence data in infants and adolescent
  • Coadministration in adolescents
  • Vaccination impact on carriage
  • Effectiveness and impact of MenB vaccination program

Pertussis Control

  • Burden of Pertussis Disease and Prevention

Measles, mumps, rubella and varicella virus prevention

  • Provide education on how to counsel parents to understand and communicate about the use of MMRV combination vaccine (focus on countries/regions utilizing combination MMRV vaccine e.g. Europe, Canada, Australia, Brazil)
  • The medical burden of varicella disease (e.g. incidence, hospitalisations, complications, Congenital Varicella Syndrome, sequelae)
  • The impact/benefit of vaccinating against varicella (both medical impact and cost effectiveness)

Rotavirus control

  • Rotavirus gastro-enteritis (RVGE) and its contribution to morbidity/mortality in patients worldwide 
  • How to raise awareness and effectively counsel parents on the importance of Rotavirus vaccination for the prevention of RVGE: experience from Health Care Providers daily practices
  • Effectiveness, impact and health economic benefits of Rotavirus vaccination in different socio-economic settings

Influenza (Flu) virus prevention

  • Childhood seasonal influenza vaccination: awareness, coverage, vaccines effectiveness, burden of disease, in North America, Europe and International.
  • Burden of disease of seasonal influenza in pregnant woman, and infants (worldwide) and experience with seasonal influenza vaccination (TIV and QIV)
  • Childhood and school based influenza vaccination programs and strategies (Introduction of new programs, impact of vaccination, herd effect/indirect protection)
  • Influenza burden of disease and impact of vaccination against different flu strains in US, Europe and International
  • Pandemic preparedness

Human Papilloma Virus (HPV) prevention

  • Cervical Cancer Disease awareness in Asia and Latin America
  • Effectiveness and safety of Cervical Cancer Prevention through vaccination
  • Effective introduction and maintenance of vaccination programs

Travel health risks prevention

  • Travel Medicine focused on pre-travel Medical Education for Primary Care Physicians, Nurses and Pharmacists with broad geographical reach including European countries
  • Travel vaccine schedules and potential outcomes of non-adherence to schedules on expected protection with broad geographical reach including European countries
  • Raise awareness of Rabies potential risk for travelers, prevention strategies and their limitations with broad geographical reach including European countries
  • Vaccine preventable diseases status amongst mobile populations (migrant workers, refugees, asylum seekers, immigrants)

Rabies prevention

  • Disease burden and prevention in endemic areas with focus on high risk populations

Tick Borne Encephalitis (TBE) prevention

  • Raise awareness of TBE burden and vaccination benefit in at risk populations

Hepatitis B Virus (HBV) prevention

  • Understanding and implementing Hepatitis B vaccination for diabetic patients, chronic liver disease patients & chronic kidney disease patients following local recommendations

General vaccination topics

  • Societal and economic barriers for providers and population to vaccine uptake for all ages (in particular for adolescents, adults and older adults)
  • Innovative solutions for educational activities aiming to increase vaccine awareness and acceptance in all ages
  • Impact of infectious diseases (IDs) and vaccine preventable IDs in older adults’ morbidity and mortality, and in relation to the frailty index
  • The aging parameters of the immune system (immunosenescence) and how they impact the immune response to vaccines of older adults vs young people
  • The role and value of vaccine solutions beyond the simple cost/benefit assessment of vaccines to support healthy aging
  • Impact of communication interventions on vaccine uptake using new digital platforms, in particular in pregnant women and adults/older adults
  • Immunity of pregnancy and how that relates to vaccination
  • Role of adjuvants in vaccines, how they help antigen(s) in mimicking or improving the activation of immune defense systems
  • Safety of modern vaccines including new technologies: myths and facts
  • Vaccine related education for Medical and healthcare schools
  • Materials, innovative tools to help people of any age understand vaccination
  • Challenges and solutions to implement life course immunisation